X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (26) 26
humans (24) 24
oncology (21) 21
lung neoplasms - drug therapy (18) 18
lung neoplasms - genetics (18) 18
carcinoma, non-small-cell lung - genetics (17) 17
mutation (17) 17
carcinoma, non-small-cell lung - drug therapy (16) 16
article (15) 15
chemotherapy (14) 14
crizotinib (14) 14
cell line, tumor (11) 11
cell lung-cancer (11) 11
ceritinib (11) 11
receptor protein-tyrosine kinases - genetics (11) 11
drug resistance, neoplasm - genetics (10) 10
lung cancer (10) 10
pyrazoles - therapeutic use (10) 10
pyridines - therapeutic use (10) 10
alk (9) 9
acquired-resistance (8) 8
antineoplastic agents - therapeutic use (8) 8
female (8) 8
middle aged (8) 8
protein kinase inhibitors - therapeutic use (8) 8
pyrimidines - therapeutic use (8) 8
sulfones - therapeutic use (8) 8
cancer (7) 7
dna repair (7) 7
hemic and lymphatic diseases (7) 7
lung neoplasms - metabolism (7) 7
nsclc (7) 7
tumors (7) 7
anaplastic lymphoma kinase (6) 6
carcinoma, non-small-cell lung - metabolism (6) 6
male (6) 6
receptor protein-tyrosine kinases - antagonists & inhibitors (6) 6
resistance (6) 6
animals (5) 5
beer (5) 5
biochemistry (5) 5
carcinoma, non-small-cell lung - pathology (5) 5
care and treatment (5) 5
chemistry (5) 5
crizotinib resistance (5) 5
drug resistance, neoplasm - drug effects (5) 5
enzymology (5) 5
ercc1 (5) 5
genetic aspects (5) 5
lung cancer, non-small cell (5) 5
lung neoplasms - pathology (5) 5
metallurgy (5) 5
microbiology (5) 5
mutation or genetic engineering (5) 5
protein kinase inhibitors - pharmacology (5) 5
protein-tyrosine kinase (5) 5
receptor protein-tyrosine kinases - metabolism (5) 5
spirits (5) 5
vinegar (5) 5
wine (5) 5
abridged index medicus (4) 4
acquired resistance (4) 4
cancer therapies (4) 4
carcinoma, non-small-cell lung - mortality (4) 4
cell biology (4) 4
dna-binding proteins - metabolism (4) 4
dna-repair (4) 4
drug resistance (4) 4
endonucleases - metabolism (4) 4
expression (4) 4
health aspects (4) 4
inhibitor (4) 4
kinases (4) 4
lactams, macrocyclic - pharmacology (4) 4
lactams, macrocyclic - therapeutic use (4) 4
lung neoplasms - mortality (4) 4
medicine, research & experimental (4) 4
metastasis (4) 4
mice (4) 4
mutations (4) 4
non-small cell lung carcinoma (4) 4
open-label (4) 4
protein-tyrosine kinases - genetics (4) 4
proteins (4) 4
proto-oncogene proteins - genetics (4) 4
research (4) 4
ros1 (4) 4
safety (4) 4
tumor cells, cultured (4) 4
tyrosine (4) 4
adult (3) 3
antineoplastic agents - pharmacology (3) 3
biopsy (3) 3
carcinoma, non-small-cell lung - diagnosis (3) 3
cell proliferation - drug effects (3) 3
cisplatin (3) 3
cisplatin - therapeutic use (3) 3
clinical trials (3) 3
compositions or test papers therefor (3) 3
condition-responsive control in microbiological orenzymological processes (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Science, ISSN 0036-8075, 12/2014, Volume 346, Issue 6216, pp. 1480 - 1486
Targeted cancer therapies have produced substantial clinical responses, but most tumors develop resistance to these drugs. Here, we describe a pharmacogenomic... 
CELL LUNG-CANCER | ALK | KINASE INHIBITION | GEFITINIB | ACTIVATION | CERITINIB | MULTIDISCIPLINARY SCIENCES | CRIZOTINIB | MUTATIONS | CHEMOTHERAPY | BYPASS MECHANISMS | Lung Neoplasms - drug therapy | Sulfones - therapeutic use | Humans | Receptor, Fibroblast Growth Factor, Type 3 - antagonists & inhibitors | MAP Kinase Kinase 1 - genetics | DNA Mutational Analysis | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Tumor Cells, Cultured | Molecular Targeted Therapy - methods | Lung Neoplasms - genetics | Receptor, Fibroblast Growth Factor, Type 3 - genetics | Lung Neoplasms - enzymology | Carcinoma, Non-Small-Cell Lung - genetics | MAP Kinase Kinase 1 - metabolism | Proto-Oncogene Proteins pp60(c-src) - antagonists & inhibitors | Patient-Specific Modeling | Drug Resistance, Neoplasm - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Enzyme Activation - genetics | Drug Screening Assays, Antitumor | Antimitotic agents | Cancer patients | Care and treatment | Lung cancer | Dosage and administration | Genetic aspects | Antineoplastic agents | Drug therapy | Drug resistance | Methods | Cancer | Cell culture | Oncology | Pharmaceutical sciences | Drugs | Mutations | Therapy | Genetics | Kinases | Patients | Tumors
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 1, pp. 54 - 61
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2013, Volume 368, Issue 12, pp. 1101 - 1110
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2013, Volume 368, Issue 25, pp. 2395 - 2401
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2019, Volume 25, Issue 8, pp. 2369 - 2371
Journal Article
Lung Cancer: Targets and Therapy, ISSN 1179-2728, 09/2019, Volume 10, pp. 87 - 94
ROS1 inhibition provides impressive survival benefits in ROS1-rearranged non-small cell lung cancer (NSCLC) patients. Crizotinib is the only tyrosine kinase... 
Tyrosine | Cell survival | Disease | Lung cancer | Non-small cell lung carcinoma | Clinical trials | Metastasis | Kinases | Cancer therapies | Chemotherapy | Mutation | Solid tumors | Protein-tyrosine kinase | Tumors | Entrectinib | ROS1 | Tyrosine kinase inhibitors
Journal Article
Nature Medicine, ISSN 1078-8956, 05/2018, Volume 24, Issue 4, pp. 512 - 517
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2019, p. clincanres.2035.2019
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 11/2014, Volume 20, Issue 22, pp. 5686 - 5696
Purpose: The first-generation ALK tyrosine kinase inhibitor (TKI) crizotinib is a standard therapy for patients with ALK-rearranged non-small cell lung cancer... 
CELL LUNG-CANCER | ANAPLASTIC LYMPHOMA KINASE | NVP-TAE684 | ONCOLOGY | CERITINIB | EML4-ALK FUSION GENE | SENSITIVITY | CH5424802 | CRIZOTINIB RESISTANCE | NEUROBLASTOMA | IDENTIFICATION | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Humans | Lung Neoplasms - metabolism | Tomography, X-Ray Computed | Dose-Response Relationship, Drug | Piperidines - pharmacology | DNA Mutational Analysis | Inhibitory Concentration 50 | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Pyrazoles - pharmacology | Pyridines - therapeutic use | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Models, Molecular | Lactams, Macrocyclic - pharmacology | Benzoquinones - pharmacology | Drug Resistance, Neoplasm - genetics | Receptor Protein-Tyrosine Kinases - genetics | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Cell Line, Tumor | Lung Neoplasms - diagnostic imaging | Protein Conformation | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - diagnostic imaging | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Carbazoles - pharmacology | Receptor Protein-Tyrosine Kinases - chemistry | gatekeeper mutation | crizotinib | ALK-rearranged NSCLC | alectinib (RO5424802 | resistance | ceritinib (LDK378)
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2015, Volume 21, Issue 1, pp. 166 - 174
Journal Article
Cancer Discovery, ISSN 2159-8274, 10/2016, Volume 6, Issue 10, pp. 1118 - 1133
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 06/2015, Volume 21, Issue 12, pp. 2745 - 2752
Journal Article
Cancer Discovery, ISSN 2159-8274, 2014, Volume 4, Issue 6, pp. 662 - 673
Journal Article